| 引用本文: | 张文,袁薇,谢华,袁海玲,赵静,王秋红.吡贝地尔联合左旋多巴治疗帕金森病的Meta分析[J].中国现代应用药学,2016,33(10):1323-1328. |
| ZHANG Wen,YUAN Wei,XIE Hua,YUAN Hailing,ZHAO Jing,WANG Qiuhong.Meta-Analysis of Piribedil Combined with Levodopa for the Treatment of Parkinson's Disease[J].Chin J Mod Appl Pharm(中国现代应用药学),2016,33(10):1323-1328. |
|
| |
|
|
| 本文已被：浏览 2001次 下载 1684次 |
码上扫一扫！ |
|
|
| 吡贝地尔联合左旋多巴治疗帕金森病的Meta分析 |
|
张文1, 袁薇2, 谢华1, 袁海玲1, 赵静1, 王秋红1
|
|
1.中国人民解放军兰州军区兰州总医院安宁分院药剂科, 兰州 730070;2.兰州大学第二医院神经内科, 兰州 730030
|
|
| 摘要: |
| 目的 系统评价吡贝地尔联合左旋多巴治疗帕金森病（Parkinson’s disease，PD）的有效性与安全性。方法 检索Cochrane library、PubMed、ScienceDirect英文数据库和CNKI、WanFang、VIP中文数据库，检索时间从建库至2015年9月，收集吡贝地尔联用左旋多巴治疗PD的随机对照试验（randomized controlled trial，RCT）。由2名研究者严格按照纳入与排除标准独立筛选文献、提取资料并评价质量，使用RevMan5.3软件进行Meta分析。结果 最终纳入9个随机对照试验，共计697例PD患者。Meta分析结果显示，吡贝地尔联合左旋多巴在改善统一帕金森病评定量表（unified Parkinson’s disease rating scale，UPDRS）总评分、UPDRS运动评分、UPDRS日常活动评分方面优于左旋多巴联合安慰剂或左旋多巴单药治疗，差异具有统计学意义[UPDRS总评分：MD=-9.20，95% CI（-11.28，-7.12），P<0.000 01；UPDRS运动评分：随访时间≤6月，MD=-3.04，95% CI（-4.92，-1.16），P=0.002；随访时间>6个月，MD=-10.81，95% CI（-14.76，-6.86），P<0.000 01；UPDRS日常活动评分：MD=-1.28，95% CI（-2.31，-0.26），P=0.01]；在胃肠道不良反应发生率方面，左旋多巴联合安慰剂或左旋多巴单药治疗优于吡贝地尔联合左旋多巴，其差异有统计学意义[OR=1.86，95% CI（1.04，3.31），P=0.04]。结论 吡贝地尔联用左旋多巴治疗PD，可显著改善UPDRS总评分、UPDRS运动评分、UPDRS日常活动评分，同时应重视其胃肠道不良反应。 |
| 关键词: 帕金森病 吡贝地尔 左旋多巴 系统评价 Meta分析 |
| DOI：10.13748/j.cnki.issn1007-7693.2016.10.025 |
| 分类号: |
| 基金项目: |
|
| Meta-Analysis of Piribedil Combined with Levodopa for the Treatment of Parkinson's Disease |
|
ZHANG Wen1, YUAN Wei2, XIE Hua1, YUAN Hailing1, ZHAO Jing1, WANG Qiuhong1
|
|
1.Department of Pharmacy, Anning Branch, Lanzhou General Hospital Lanzhou Command, CPLA, Lanzhou 730070, China;2.Department of Neurology, Lanzhou University Second Hospital, Lanzhou 730030, China
|
| Abstract: |
| OBJECTIVE To evaluate the safety and efficacy of piribedil combined with levodopa in the treatment of Parkinson's disease (PD). METHODS Randomized controlled trials of piribedil combined with levodopa for PD were gathered from Cochrane Library, PubMed, Science Direct, CNKI, WanFang and VIP from their establishment to September 2015. Two reviewers independently screened the studies, extracted the data and assessed the quality according to the inclusion and exclusion criteria. The Meta-analysis was conducted with RevMan 5.3 software. RESULTS A total of 9 randomized controlled trials (RCTs) involving 697 PD patients were included. The results of Meta-analysis showed that compare with placebo plus levodopa or levodopa, piribedil plus levodopa significantly greater improvements in total unified Parkinson's disease rating scale (UPDRS) scores, motor UPDRS scores and activities of daily living UPDRS scores in participants with PD with statistically differences[Total UPDRS scores:MD=-9.20, 95%CI(-11.28,-7.12), P<0.000 01; Motor UPDRS scores:Follow-up time was less than or equal to 6 months, MD=-3.04, 95%CI(-4.92, -1.16), P=0.002; Follow-up time was more than 6 months, MD=-10.81, 95%CI(-14.76, -6.86), P<0.000 01; activities of daily living UPDRS scores:MD=-1.28, 95%CI(-2.31, -0.26), P=0.01], and more gastrointestinal adverse events incidences with statistically differences[OR=1.86, 95%CI(1.04, 3.31), P=0.04]. CONCLUSION Piribedil in addition to levodopa is an effective combination therapy for PD, and significantly improvements in total UPDRS scores, motor UPDRS scores and activities of daily living UPDRS scores, and we should more focus on the gastrointestinal adverse events too. |
| Key words: Parkinson's disease piribedil levodopa systematic review meta-analysis |
|
|
|
|
